Global Non-Injectable Insulin Market to Grow with a CAGR of 9.63% through 2030
Rising Prevalence of Diabetes
is expected to drive the Global Non-Injectable Insulin Market growth in the
forecast period, 2026-2030.
According to TechSci Research
report, “Non-Injectable Insulin Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2030”, the Global Non-Injectable Insulin
Market at USD 3.14 Billion in 2024 and is anticipated to project robust growth
in the forecast period with a CAGR of 9.63% through 2030. The market for Non-Injectable
Insulin devices has witnessed consistent growth over the Advancements in drug
delivery technologies. The development of stable oral insulin formulations that
can withstand the digestive process while maintaining efficacy has opened up
new avenues for non-injectable insulin therapies. As diabetes becomes more
prevalent, the need for diverse treatment methods becomes more pronounced,
boosting the adoption of non-injectable insulin solutions. Pharmaceutical
companies are investing significantly in research and development to enhance
non-injectable insulin technologies. This commitment to innovation has resulted
in the development of more efficient and patient-friendly delivery methods,
expanding the market's reach and potential. These drivers collectively
contribute to the market's growth trajectory and its pivotal role in
revolutionizing diabetes care by providing more accessible and effective
treatment options.
Also, Efficacy and Safety
Concerns and strict regulatory approval for non-injectable insulin products can
hamper the growth of Global Non-Injectable Insulin Market. Similarly, Device
malfunctions, user errors, or difficulties in administration can restrain the
growth of Global Non-Injectable Insulin Market. Additionally, Accessibility and
affordability of non-injectable insulin will further restrict the growth of Global
Non-Injectable Insulin Market.
Browse over xx market
data Figures spread through xx Pages and an in-depth TOC on "Global
Non-Injectable Insulin Market”
The Global Non-Injectable Insulin
Market is segmented into Product, Distribution Channel and Region.
Based
on Distribution Channel, the Drug Stores segment shows the fastest growth over the forecast period. This can be attributed to the Drug stores
serve a diverse range of patients, including those with varying needs and
preferences. This diversity makes drug stores an ideal setting for promoting
and offering non-injectable insulin products. Pharmacists at drug
stores can counsel patients on the benefits of non-injectable insulin methods.
This counseling can address patient concerns, answer questions, and provide
reassurance, leading to increased patient acceptance. Some drug stores offer
health screenings, including blood glucose testing. Pharmacists can use these
opportunities to educate patients about non-injectable insulin methods and encourage
them to consider these alternatives.
Based on the region, The Asia Pacific region is witnessing significant growth in the Non-Injectable Insulin Market, driven by the rising prevalence of diabetes, increasing healthcare awareness, and advancements in insulin delivery technologies. Countries such as China, India, and Japan are leading the expansion due to large diabetic populations, growing healthcare expenditure, and government initiatives aimed at diabetes management. Additionally, pharmaceutical companies are actively investing in the development of oral and inhalable insulin formulations to cater to the increasing demand for needle-free alternatives. Technological innovations, collaborations between key industry players, and the approval of novel insulin products are further accelerating market growth. Moreover, the expansion of distribution networks and improved accessibility to advanced treatments contribute to the region's rapid market development.
Major companies
operating in Global Non-Injectable Insulin Market are:
- Midatech Pharma Plc
- Shreya Life Sciences Pvt.
Ltd.
- Boston Therapeutics, Inc.
- Coromed, Inc.
- Diabetology Ltd.
- Emisphere Technologies, Inc.
- Oramed Pharmaceuticals, Inc.
- Diasome Pharmaceuticals,
Inc.
- Generex Biotechnology Corp.
- Biodel, Inc.
Download Free Sample Report
Customers can also request for 10% free customization on
this report.
“The North America region is expected
to witness significant growth of Global Non-Injectable Insulin market due to rising
geriatric & target populations, increasing number of collaborations for the
development of biosimilars, geographic expansion of key players, and active
participation of government & nonprofit organizations in the market space. Furthermore,
health awareness campaigns and scientific conferences for the management of
this disease may fuel market growth in the region. Furthermore, many companies
are rapidly opting for geographical expansion, strategic collaborations, and
partnerships in emerging and economically favorable regions through mergers and
acquisitions which will further drive the growth of the market during the
forecast period. The growing use of digital technologies including insulin
pumps or continuous glucose monitoring devices, is on the rise as a way to
improve insulin delivery also monitoring is the major factor driving the growth
of the global Non-Injectable Insulin Market during the forecast period” said Mr.
Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Non-Injectable Insulin
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Pills, Sprays, and Others), By Distribution
Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores), By
Region and Competition, 2020-2030F”, has evaluated the future
growth potential of Global Non-Injectable Insulin Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Non-Injectable Insulin Market.
Contact
TechSci Research LLC
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: sales@techsciresearch.com
Web: https://www.techsciresearch.com